Introduction
============

Adverse drug reactions (ADRs) are a major public health problem in older populations.[@ref1] [@ref2] [@ref3] In Western countries, ADRs cause 3-6% of all hospital admissions[@ref1] [@ref2] [@ref3] and are responsible for about 5-10% of inpatient costs.[@ref4] [@ref5] [@ref6] We have previously reported that repeat ADRs resulting in either hospital admission or extended hospital stay increased at a greater rate than first time ADRs in older adults from 1980-2003. Furthermore, in Western Australia by 2003 over 30% of all ADRs were repeat ADRs.[@ref7]

Despite concerns that ADRs represent an important medical problem in older people, the predictive factors are still poorly understood. Older patients are vulnerable to ADRs because of the multiple drugs that they receive to manage chronic diseases and also because of changes in pharmacokinetics and pharmacodynamics.[@ref8] [@ref9] Risk factors reported to be independently associated with ADRs have included advancing age, sex, comorbidity, multiple drug regimens, inappropriate use of medication, alcohol intake, poor cognitive function, and depression.[@ref4] [@ref10] [@ref11] [@ref12] [@ref13] [@ref14] [@ref15] There is currently no consensus on which factors have the greatest impact.

We conducted a retrospective cohort study based on a state-wide population of patients to investigate whether or not comorbid conditions, age and other demographic factors, and drug category are associated with a repeat admission for ADRs in people aged ≥60.

Methods
=======

Study setting and population
----------------------------

We used administrative data from all public and private hospitals in Western Australia, a state with a population of 2.09 million in 2007.[@ref16] The study population consisted of all residents aged ≥60 with a hospital admission related to an ADR identified through the data linkage system. This system links state-wide administrative health data at the individual level using probabilistic matching of patients' names and other identifiers with clerical review of doubtful matches. It includes links between seven core datasets, of which the statutory death registry from 1969 and the hospital morbidity data system (HMDS) from 1970 form the main parts.[@ref17] We used extracts of linked hospital morbidity records and death records, with encryption to protect the identity of individual patients. The data were extracted in February 2005.

The hospital morbidity data system contained information on encrypted patient identification and episode number; age, sex, indigenous status, and postcode; date of admission and date of separation (that is, transfer, discharge, or inpatient death); international classification of diseases (ICD) codes for the main diagnosis and up to 19 additional diagnoses for up to four external causes (E codes), and for the main procedure and up to 10 additional procedures; type of hospital attended (public, private, other), admission type (emergency or elective), and payment classification. We used ICD-9 for 1980-7,[@ref18] ICD-9-CM for 1988-June 1999,[@ref19] and ICD-10-AM from July 1999 onwards.[@ref20] Data from the death records included encrypted patient identification, age, sex, indigenous status, primary cause of death, date of death, and postcode. We extracted linked hospital and death records for all patients aged ≥60 with an admission for ADR in 1980-2003 in Western Australia. In an assessment of the technical performance of the linkage system in finding true matches between records, both the proportion of invalid links (false positives) and of missed links (false negatives) was estimated to be 0.11%.[@ref17]

Definition of ADR and identification of patients
------------------------------------------------

We included all ADRs that resulted in hospital admission or that occurred while patients were in hospital and extended the length of hospital stay. An ADR event was defined as any hospital separation with an ICD E code indicating that either the admission or extended hospital stay was because of the adverse effects of drugs, medicines, and biological substances in therapeutic use: E930--E949 (ICD-9 and ICD-9-CM) or Y40--Y59 (ICD-10-AM). The codes included any adverse effect caused by correct use of drugs, medicines, or biological substances properly administered in therapeutic or prophylactic doses, excluding errors in the technique of administration of drugs, intentional and unintentional overdose, and abuse of a drug. Thus, our definition of ADRs was consistent with the more recent and clearer version: "An appreciably harmful or unpleasant reaction, resulting from an intervention related to the use of a medicinal product, which predicts hazard from future administration and warrants prevention or specific treatment, or alteration of the dosage regimen, or withdrawal of the product."[@ref21] An ADR hospital episode was defined as a period of continuous treatment for an ADR in one or more hospitals, as a person might have been transferred from one hospital to another before they were discharged. We checked all records for transfers between hospitals and, where they existed, combined the admissions into a single "episode" for analysis.

To ensure correct identification of first time ADRs, we initially examined all admissions of the patients dating back to 1970. We included 803 732 hospital separations and audited these records to ensure that each patient met the selection criteria. We excluded people who were not residents of Western Australia and those with hospital episodes unrelated to ADRs. There were 37 296 patients who lived and were treated in Western Australia and had at least one admission episode for an ADR. Each patient's first ADR record was identified, thereby distinguishing first time from repeat episodes. We included 28 548 patients with a first time ADR in 1980-2000 as a cohort and followed them up for three years. The figure shows the process of selecting patients for the study[](#fig1){ref-type="fig"}.

![Process of selecting patients for study from the Western Australia data linkage system](zham555482.f1){#fig1}

Follow-up and outcome measurements
----------------------------------

The length of follow-up was the time in days from hospital separation for the first time ADR episode (time zero) to the date of a second separate admission for an ADR or, in the absence of a repeat event within three years, to the date of the third anniversary from time zero or date of death if within three years (censored).

We identified the drugs responsible for first time ADRs from the E codes on the hospital morbidity data system. In the 3.9% of all instances when multiple drugs were thought to be responsible for an ADR we included in the analysis only the drug clinically considered to be primarily responsible. Drugs were grouped into 20 broad categories as defined in ICD-10-AM, with closest possible equivalent specifications for ICD-9 and ICD-9-CM. Table 1 shows the distributions of admissions for first time ADRs according to these drug categories and details the modifications required in the drug categories caused by differences between ICD-9/ICD-9-CM and ICD-10-AM.[](#tbl1){ref-type="table"} Table 2 gives more specific details of the top 30 drug groups most often implicated in first time ADRs at the four digit E code level (ICD-9/ICD-9-CM) and three digit Y code level (ICD-10-AM), which accounted for more than 81% of all episodes in the study.[](#tbl2){ref-type="table"}

###### 

Drug categories (from ICD external cause codes) responsible for admission for first time adverse drug reaction (ADR) in patients aged ≥60, Western Australia, 1980-2000

  Drug category (as defined in ICD-10-AM)               ICD-9/ICD-9-CM   ICD-10-AM   No (%) of patients
  ----------------------------------------------------- ---------------- ----------- --------------------
  Systemic antibiotics\*                                E930             Y40         2672 (9.4)
  Other systemic anti-infectives/antiparasitics         E931             Y41         430 (1.5)
  Hormones (including synthetics and antagonists)       E932             Y42         2174 (7.6)
  Primarily systemic agents                             E933             Y43         2122 (7.4)
  Agents primarily affecting blood constituents         E934             Y44         2432 (8.5)
  Analgesics/antipyretics/anti-inflammatory drugs       E935             Y45         4694 (16.4)
  Antiepileptics/antiparkinsonian drugs                 E936             Y46         1121 (3.9)
  Sedatives, hypnotics, antianxiety drugs               E937             Y47         406 (1.4)
  Anaesthetics and therapeutic gases                    E938             Y48         414 (1.5)
  Psychotropic drugs†                                   E939             Y49         1534 (5.4)
  Central nervous system stimulants                     E940             Y50         18 (0.1)
  Drugs primarily affecting autonomic nervous system‡   E941             Y51         476 (1.7)
  Agents primarily affecting cardiovascular system      E942             Y52         5576 (19.5)
  Agents primarily affecting gastrointestinal system    E943             Y53         252 (0.9)
  Agents affecting water balance/minerals/uric acid§    E944             Y54         2024 (7.1)
  Agents affecting muscles/respiratory system           E945             Y55         563 (2.0)
  Topical agents affecting skin, eyes, ENT, dental      E946             Y56         577 (2.0)
  Other and unspecified drugs and medicines             E947             Y57         982 (3.4)
  Bacterial vaccines                                    E948             Y58         16 (0.1)
  Other and unspecified vaccines/biologicals            E949             Y59         65 (0.2)
  Total                                                                              28 548 (100.0)

ADR=adverse drug reaction; ICD=International Classification of Diseases; ENT=ear, nose, throat.

\*Excludes antineoplastic antibiotics (E930.7) from ICD-9/ICD-9-CM (were added to primarily systemic agents, which include antineoplastics).

†Excludes benzodiazepines (E939.4) from ICD-9/ICD-9-CM (were added to group sedatives, hypnotics, antianxiety drugs, which includes benzodiazepines in ICD-10).

‡Excludes sympatholytics (E941.3) from ICD-9/ICD-9-CM (were added to agents primarily affecting cardiovascular system, which include these in ICD-10).

§Excludes theophylline (E944.1) from ICD-9/ICD-9-CM (was added to agents affecting muscles/respiratory system, which includes antiasthmatics).

###### 

Top 30 drug groups (ICD E codes) most often implicated in admission for first time adverse drug reaction (ADR) in 28 548 patients aged ≥60, Western Australia, 1980-2000

  Drug groups (as defined in ICD-10-AM)                           ICD-9/ICD-9-CM   ICD-10-AM   No (%) of patients
  --------------------------------------------------------------- ---------------- ----------- --------------------
  Systemic antibiotics:                                                                        
   Penicillins                                                    E930.0           Y40.0       881 (3.1)
   Unspecified systemic antibiotics                               E930.9           Y40.9       569 (2.0)
   Other systemic antibiotics                                     E930.8           Y40.8       505 (1.8)
   Cephalosporins and other β lactams                             E930.5           Y40.1       353 (1.2)
  Hormones (including synthetics and antagonists):                                             
   Glucocorticoids and synthetics                                 E932.0           Y42.0       1328 (4.7)
   Insulins and oral antidiabetic drugs                           E932.3           Y42.3       416 (1.5)
  Primarily systemic agents:                                                                   
   Antineoplastic/immunosuppressive drugs                         E933.1/E930.7    Y43.1-4     1980 (6.9)
  Agents primarily affecting blood constituents:                                               
   Anticoagulants                                                 E934.2           Y44.2       1964 (6.9)
   Thrombolytic drugs                                             E934.4           Y44.5       247 (0.9)
  Analgesics/antipyretics/anti-inflammatory drugs:                                             
   NSAIDs and antirheumatics                                      E935.6           Y45.2-4     2026 (7.1)
   Opioids and related analgesics                                 E935.2           Y45.0       1388 (4.9)
   Salicylates                                                    E935.3           Y45.1       442 (1.5)
   4-aminophenol derivatives (such as paracetamol)                E935.4           Y45.5       361 (1.3)
  Antiepileptics and antiparkinsonian drugs:                                                   
   Hydantoin derivatives                                          E936.1           Y46.2       408 (1.4)
   Antiparkinsonian drugs                                         E936.4           Y46.7       359 (1.3)
   Other and unspecified antiepileptics                           E936.3           Y46.6       302 (1.1)
  Psychotropic drugs:                                                                          
   Antidepressants                                                E939.0           Y49.0-2     596 (2.1)
   Phenothiazine antipsychotics/neuroleptics                      E939.1           Y49.3       365 (1.3)
  Agents primarily affecting cardiovascular system:                                            
   Cardiac stimulant glycosides/similar drugs                     E942.1           Y52.0       1702 (6.0)
   Other antihypertensive drugs                                   E942.6           Y52.5       1708 (6.0)
   Other antidysrhythmic drugs                                    E942.0           Y52.2       786 (2.8)
   Coronary vasodilators                                          E942.4           Y52.3       662 (2.3)
   Peripheral vasodilators (ICD-9 sympatholytics)                 E941.3           Y52.7       269 (0.9)
  Agents affecting water balance, mineral/uric acid metabolism:                                
   Loop and other diuretics                                       E944.4           Y54.4-5     1257 (4.4)
   Benzothiadiazine derivatives                                   E944.3           Y54.3       322 (1.1)
   Uric acid metabolism drugs (such as colchicine)                E944.7           Y54.8       242 (0.8)
  Agents affecting muscles/respiratory system:                                                 
   Antiasthmatics (including theophylline)                        E944.1/E945.7    Y55.6       472 (1.7)
  Topical agents affecting skin, eyes, ENT, dental:                                            
   Local anti-infectives/anti-inflammatory drugs                  E946.0           Y56.0       435 (1.5)
  Other and unspecified drugs and medicines:                                                   
   Unspecified drug or medicines                                  E947.9           Y57.9       555 (1.9)
   Other drugs or medicines                                       E947.8           Y57.8       354 (1.2)
  Total                                                                                        23 254 (81.5)

ADR=adverse drug reaction; ICD=International Classification of Diseases; NSAIDs=non-steroidal anti-inflammatory drugs; ENT=ear, nose, throat.

Comorbidity was measured by using the Charlson comorbidity index[@ref22] conditions mentioned in the hospital record for the first time ADR, coded to an ICD-9, ICD-9-CM, or ICD-10-AM rubric that were different from the principal index diagnosis. Nineteen fields existed within the hospital morbidity data system for recording comorbid conditions. The performance of the linkage system in adjusting for comorbidty in longitudinal research designs has been previously demonstrated.[@ref23] [@ref24] We calculated the Charlson score by adding scores assigned to each specific diagnosis, which was generated using the Dartmouth-Manitoba algorithms for ICD coded administrative data.[@ref25] [@ref26] Table 3 shows Charlson comorbid conditions (with weights) present at the admission for first time ADR.[](#tbl3){ref-type="table"}

###### 

 Charlson comorbidity conditions (with weights) present at admission for first time adverse drug reaction (ADR) in 28 548 patients aged ≥60, Western Australia, 1980-2000

  Charlson comorbid conditions                   Weight   No (%) of patients
  ---------------------------------------------- -------- --------------------
  Myocardial infarction                          1        1556 (5.5)
  Congestive cardiac failure                     1        4745 (16.6)
  Peripheral vascular disease                    1        1174 (4.1)
  Cerebrovascular disease                        1        1827 (6.4)
  Dementia                                       1        868 (3.0)
  Chronic pulmonary disease                      1        2034 (7.1)
  Rheumatological disease                        1        832 (2.9)
  Peptic ulcer disease                           1        2145 (7.5)
  Mild liver disease                             1        199 (0.7)
  Diabetes (mild to moderate)                    1        2807 (9.8)
  Diabetes with complications                    2        755 (2.6)
  Hemiplegia or paraplegia                       2        864 (3.0)
  Renal disease                                  2        1418 (5.0)
  Any malignancy, including lymphoma/leukaemia   2        3349 (11.7)
  Moderate or severe liver disease               3        108 (0.4)
  Metastatic solid tumour                        6        1518 (5.3)
  AIDS                                           6        5 (0.0)

We assigned a socioeconomic disadvantage score for each patient by transforming residential postcode into numerical values of the index of relative socioeconomic disadvantage compiled from the 1986, 1991, 1996, and 2001 Australian censuses and applied to 1980-8, 1989-93, 1994-8, and 1999-2003, respectively.[@ref27] The index was developed by the Australian Bureau of Statistics and consists of four variables that reflect or measure relative disadvantage, including low income, low educational attainment, high unemployment, and low skilled occupation; it has been used extensively in public health research.[@ref27] The continuous values of the indexes were then partitioned into fifths.

Statistical analysis
--------------------

Statistical analysis was performed with SPSS version 12.0.1 (SPSS, Chicago, IL). We used the independent samples *t*test for continuous variables and a χ^2^ test for categorical variables to compare characteristics between patients with first time only and repeat ADR episodes. Variables associated with first time admissions for an ADR were used for univariate and multivariate analysis. Univariate analysis was undertaken to screen for potentially important variables to be used in the subsequent multivariate analysis. Multivariate Cox proportional hazards regression models were fitted by using all variables included as main effects terms, and we performed corresponding linear trend tests. When assessing each drug category, we fitted the Cox regression models using deviation coding, which compared the effect on repeat ADRs of each first time drug category with the average risk of all 20 drug categories. We obtained hazard ratios and associated 95% confidence intervals after adjusting for age, sex, indigenous status, residential locality, socioeconomic disadvantage, admission type, hospital type, length of hospital stay, calendar period of ADR, Charlson comorbidity index, and drug categories. Other studies have identified these variables as those influencing the risk of first time ADRs,[@ref10] [@ref11] [@ref12] [@ref13] [@ref14] [@ref15] and they were significant predictors of repeat ADRs based on the preceding univariate analysis. To assess potential for survival bias, we separately analysed data from all patients and from a subset that excluded those who died in the three year follow-up period.

Results
=======

Results using data from all patients were similar to those obtained when we excluded patients who died in the follow-up period. We have therefore reported only the results from analyses that included all patients. Within the first three years of follow-up, 5056 patients (17.7%) experienced a repeat admission for an ADR. Table 4[](#tbl4){ref-type="table"} presents unadjusted and adjusted hazard ratios for repeat ADRs for selected characteristics in the participants. The adjusted hazard ratios for repeat ADRs were 1.08 (95% confidence interval 1.02 to 1.15) for men, 0.87 (0.80 to 0.93) for private hospital admissions, 1.11 (1.05 to 1.18) for length of hospital stay ≥14 days, 2.34 (2.00 to 2.73) for admission in 1995-9 compared with the earliest time period, and 1.71 (1.46 to 1.99) for a Charlson comorbidity index score ≥7, with a significant linear trend across quantitative or ordinal quantitative variables. Residential location in the metropolitan area (1.10, 1.01 to 1.19) was marginally significant (P=0.03). There was no significant effect on repeat ADRs for age, indigenous status, type of admission, and socioeconomic disadvantage.

###### 

 Unadjusted and adjusted hazard ratios (with 95% confidence intervals) of repeat adverse drug reaction (ADRs) for selected characteristics in older adults

  Characteristics at first admission for ADR   First time ADR only (n=23 492)   Repeat ADR (n=5056)   Unadjusted                      Adjusted                      
  -------------------------------------------- -------------------------------- --------------------- --------------------- --------- --------------------- ------- ---------
  Age at admission (years):                                                                                                                                         
   60-64                                       3226                             790                   1.00‡                 0.18                            1.00‡   0.39
   65-69                                       3830                             870                   0.96 (0.87 to 1.05)             0.97 (0.88 to 1.07)           
   70-74                                       4697                             982                   0.90 (0.82 to 0.99)             0.93 (0.84 to 1.02)           
   75-79                                       4647                             1009                  0.95 (0.86 to 1.04)             0.99 (0.91 to 1.10)           
   ≥80                                         7092                             1405                  0.92 (0.84 to 1.00)             0.96 (0.87 to 1.05)           
  Sex:                                                                                                                                                              
   Female                                      13 264                           2810                  1.00‡                 \<0.001                         1.00‡   \<0.01
   Male                                        10 228                           2246                  1.13 (1.07 to 1.19)             1.08 (1.02 to 1.15)           
  Indigenous status:                                                                                                                                                
   Non-Aboriginal/TSI                          23 288                           5006                  1.00‡                 0.34                            1.00‡   0.85
   Aboriginal/TSI                              204                              50                    1.15 (0.87 to 1.52)             1.03 (0.77 to 1.37)           
  Residential locality:                                                                                                                                             
   Regional/rural area                         3936                             847                   1.00‡                 0.53                            1.00‡   0.03
   Metropolitan Perth                          19 556                           4209                  1.02 (0.95 to 1.10)             1.10 (1.01 to 1.19)           
  Admission type:                                                                                                                                                   
   Elective                                    6469                             1405                  1.00‡                 0.75                            1.00‡   0.13
   Emergency                                   17 007                           3648                  1.01 (0.95 to 1.07)             1.05 (0.99 to 1.12)           
  Type of hospital attended:                                                                                                                                        
   Public                                      19 542                           4063                  1.00‡                 \<0.001                         1.00    \<0.001
   Private                                     3275                             930                   1.32 (1.23 to 1.42)             0.87 (0.80 to 0.93)           
   Other                                       675                              63                    0.41 (0.32 to 0.53)             0.80 (0.61 to 1.04)           
  Length of hospital stay (days):                                                                                                                                   
   \<14                                        15 803                           3408                  1.00‡                 \<0.001                         1.00‡   0.001
   ≥14                                         7689                             1648                  1.14 (1.08 to 1.21)             1.11 (1.05 to 1.18)           
  Socioeconomic disadvantage (fifths):                                                                                                                              
   1 (most)                                    4671                             982                   1.00‡                 \<0.001                         1.00‡   0.15
   2                                           5495                             1055                  0.92 (0.85 to 1.01)             0.90 (0.83 to 0.99)           
   3                                           3184                             710                   1.05 (0.96 to 1.16)             0.99 (0.90 to 1.09)           
   4                                           3365                             733                   1.04 (0.95 to 1.15)             0.95 (0.86 to 1.04)           
   5 (least)                                   6752                             1575                  1.11 (1.02 to 1.20)             0.94 (0.87 to 1.02)           
  Calendar period of ADR:                                                                                                                                           
   1980-4                                      2097                             183                   1.00‡                 \<0.001                         1.00‡   \<0.001
   1985-9                                      3540                             459                   1.48 (1.25 to 1.76)             1.44 (1.21 to 1.72)           
   1990-4                                      5915                             780                   1.53 (1.31 to 1.80)             1.52 (1.29 to 1.79)           
   1995-9                                      9409                             1946                  2.37 (2.03 to 2.75)             2.34 (2.00 to 2.73)           
  Charlson comorbidity index score:                                                                                                                                 
   0                                           9511                             1719                  1.00‡                 \<0.001                         1.00‡   \<0.001
   1-2                                         10 220                           2396                  1.46 (1.38 to 1.56)             1.30 (1.22 to 1.38)           
   3-4                                         2262                             579                   1.86 (1.69 to 2.04)             1.42 (1.29 to 1.57)           
   5-6                                         563                              151                   2.82 (2.38 to 3.33)             2.04 (1.72 to 2.42)           
   ≥7                                          936                              211                   3.10 (2.68 to 3.58)             1.71 (1.46 to 1.99)           

TSI=Torres Strait Islander.

\*Test for trend or standard P value across quantitative or ordinal quantitative variables.

†Estimates from Cox regression model included terms for age (continuous), sex (female, male), indigenous status (non-Aboriginal, Aboriginal), residence (regional/rural area, metropolitan), admission type (elective, emergency), type of hospital attended (public, private, other), length of stay (continuous), socioeconomic disadvantage (fifths), calendar period of ADR (continuous), Charlson comorbidity index score (continuous), and drug categories responsible for first time ADR.

‡Reference category.

Table 5 shows the effects of individual Charlson comorbid conditions on repeat ADRs[](#tbl5){ref-type="table"}. Compared with patients who had no recorded comorbidity, the analysis identified sizeable adjusted hazard ratios for congestive cardiac failure (1.56, 1.43 to 1.71), peripheral vascular disease (1.27, 1.09 to 1.48), chronic pulmonary disease (1.61, 1.45 to 1.79), rheumatological disease (1.65, 1.41 to 1.92), mild liver disease (1.48, 1.05 to 2.07), mild to moderate diabetes (1.18, 1.07 to 1.30), diabetes with chronic complications (1.91, 1.65 to 2.22), renal disease (1.93, 1.71 to 2.17), any malignancy including lymphoma and leukaemia (1.87, 1.68 to 2.09), moderate to severe liver disease (1.85, 1.18 to 2.92), and metastatic solid tumour (2.25, 1.92 to 2.64). Cerebrovascular disease (0.85, 0.73 to 0.98), dementia (0.62, 0.49 to 0.78), and hemiplegia or paraplegia (0.73, 0.59 to 0.89) were apparently preventive for repeat ADRs. There was no significant relation for myocardial infarction, peptic ulcer disease, or AIDS, although people with AIDS had only two repeat ADRs.

###### 

 Adjusted hazard ratios (HR) with 95% confidence intervals for repeat adverse drug reactions (ADRs) for Charlson comorbidity at first admission to hospital for ADR in older adults

  Comorbid conditions                               No (%) with first time ADR only   No (%) with repeat ADR   Adjusted HR (95% CI)\*   P value†
  ------------------------------------------------- --------------------------------- ------------------------ ------------------------ ----------
  Congestive cardiac failure                        3858 (16.4)                       889 (17.6)               1.56 (1.43 to 1.71)      \<0.001
  Peripheral vascular disease                       978 (4.2)                         196 (3.9)                1.27 (1.09 to 1.48)      \<0.01
  Chronic pulmonary disease                         1537 (6.5)                        497 (9.8)                1.61 (1.45 to 1.79)      \<0.001
  Rheumatological disease                           622 (2.6)                         210 (4.2)                1.65 (1.41 to 1.92)      \<0.001
  Mild liver disease                                164 (0.7)                         35 (0.7)                 1.48 (1.05 to 2.07)      0.03
  Diabetes (mild to moderate)                       2276 (9.7)                        531 (10.5)               1.18 (1.07 to 1.30)      \<0.01
  Diabetes with chronic complications               507 (2.2)                         248 (4.9)                1.91 (1.65 to 2.22)      \<0.001
  Renal disease                                     1045 (4.4)                        373 (7.4)                1.93 (1.71 to 2.17)      \<0.001
  Any malignancy including lymphoma and leukaemia   2538 (10.8)                       811 (16.0)               1.87 (1.68 to 2.09)      \<0.001
  Moderate or severe liver disease                  89 (0.4)                          19 (0.4)                 1.85 (1.18 to 2.92)      \<0.01
  Metastatic solid tumour                           1245 (5.3)                        273 (5.4)                2.25 (1.92 to 2.64)      \<0.001
  Cerebrovascular disease                           1601 (6.8)                        226 (4.5)                0.85 (0.73 to 0.98)      0.02
  Dementia                                          791 (3.4)                         77 (1.5)                 0.62 (0.49 to 0.78)      \<0.001
  Hemiplegia or paraplegia                          762 (3.2)                         102 (2.0)                0.73 (0.59 to 0.89)      \<0.01
  Myocardial infarction                             1332 (5.7)                        224 (4.4)                0.98 (0.84 to 1.13)      0.73
  Peptic ulcer disease                              1847 (7.9)                        298 (5.9)                1.09 (0.95 to 1.25)      0.24
  AIDS                                              3 (\<0.1)                         2 (\<0.1)                1.65 (0.41 to 6.71)      0.48

\*Estimates from Cox regression models included terms for age (continuous), sex (female, male), indigenous status (non-Aboriginal, Aboriginal), residence (regional/rural area, metropolitan), admission type (elective, emergency), type of hospital attended (public, private, other), length of stay (continuous), socioeconomic disadvantage (fifths), calendar period of ADR (continuous), and drug categories responsible for first-time ADR.

†For hazard ratio (HR), using patients with absent comorbidity as reference category.

Table 6 shows the effect of each drug category (as defined in ICD-10-AM) responsible for first time ADRs[](#tbl6){ref-type="table"}. Three drug categories were associated with a greater than average risk of repeat ADRs, with adjusted hazard ratios of 1.51 (1.34 to 1.69) for hormones, 2.12 (1.89 to 2.38) for primarily systemic agents (including antineoplastics, immunosuppressives, and antineoplastic antibiotics), and 4.06 (2.00 to 8.26) for bacterial vaccines. The latter category, however, had low counts for first time and repeat ADRs.

###### 

 Adjusted hazard ratios (with 95% confidence intervals) of repeat adverse drug reactions (ADRs) for primary drug category responsible for first time ADRs in older adults

  Drug category\*                                                          No (%) with first time ADR only   No (%) with repeat ADR   Adjusted HR (95% CI)†   P value‡
  ------------------------------------------------------------------------ --------------------------------- ------------------------ ----------------------- ----------
  E930/Y40 Systemic antibiotics§                                           2249 (9.6)                        423 (8.4)                0.81 (0.45 to 1.50)     0.53
  E931/Y41 Other systemic anti-infectives/antiparasitics                   365 (1.6)                         65 (1.3)                 1.02 (0.80 to 1.30)     0.89
  E932/Y42 Hormones (including synthetic and antagonists)                  1649 (7.0)                        525 (10.4)               1.51 (1.34 to 1.69)     \<0.001
  E933/Y43 Primarily systemic agents                                       1456 (6.2)                        666 (13.2)               2.12 (1.89 to 2.38)     \<0.001
  E934/Y44 Agents primarily affecting blood constituents                   1980 (8.4)                        452 (8.9)                0.93 (0.82 to 1.05)     0.23
  E935/Y45 Analgesics/antipyretics/anti-inflammatory drugs                 4006 (17.1)                       688 (13.6)               0.76 (0.68 to 0.84)     \<0.001
  E936/Y46 Antiepileptics/antiparkinsonian drugs                           903 (3.8)                         218 (4.3)                1.13 (0.97 to 1.32)     0.12
  E937/Y47 Sedatives, hypnotics, antianxiety drugs                         356 (1.5)                         50 (1.0)                 0.74 (0.56 to 0.97)     0.03
  E938/Y48 Anaesthetics, therapeutic gases                                 372 (1.6)                         42 (0.8)                 0.52 (0.39 to 0.71)     \<0.001
  E939/Y49 Psychotropic drugs§                                             1266 (5.4)                        268 (5.3)                0.96 (0.83 to 1.11)     0.56
  E940/Y50 Central nervous system stimulants                               15 (0.1)                          3 (0.1)                  0.76 (0.26 to 2.22)     0.61
  E941/Y51 Drugs primarily affecting autonomic nervous system§             377 (1.6)                         99 (2.0)                 0.87 (0.71 to 1.07)     0.18
  E942/Y52 Agents primarily affecting cardiovascular system                4702 (20.0)                       874 (17.3)               0.93 (0.84 to 1.04)     0.21
  E943/Y53 Agents primarily affecting gastrointestinal system              220 (0.9)                         32 (0.6)                 0.64 (0.46 to 0.90)     0.01
  E944/Y54 Agents affecting water balance/minerals/uric acid metabolism§   1703 (7.2)                        321 (6.4)                0.99 (0.86 to 1.13)     0.96
  E945/Y55 Agents affecting muscle/respiratory system                      490 (2.1)                         73 (1.4)                 1.01 (0.80 to 1.27)     0.96
  E946/Y56 Topical agents affecting skin, ENT, dental                      496 (2.1)                         81 (1.6)                 0.86 (0.69 to 1.07)     0.18
  E947/Y57 Other and unspecified drugs and medicines                       824 (3.5)                         158 (3.1)                1.02 (0.86 to 1.21)     0.80
  E948/Y58 Bacterial vaccines                                              9 (\<0.1)                         7 (0.1)                  4.06 (2.00 to 8.26)     \<0.001
  E949/Y59 Other and unspecified vaccines/biologicals                      54 (0.2)                          11 (0.2)                 0.96 (0.54 to 1.69)     0.88

\*See table 1 for more explicit specifications of ICD-9/ICD-9-CM and ICD-10-CM code definitions.

†Estimates from Cox regression model included terms for age (continuous), sex (female, male), indigenous status (non-Aboriginal, Aboriginal), residence (regional/rural area, metropolitan), admission type (elective, emergency), type of hospital attended (public, private, other), length of stay (continuous), socioeconomic disadvantage (fifths), calendar period of ADR (continuous), and Charlson comorbidity index score (continuous).

‡P value for each drug category responsible for first time ADR compared with overall effect of drug categories.

§See table 1 for details of modification in drug category between coding systems.

Discussion
==========

Predictive factors for repeat ADR admission
-------------------------------------------

In this population based cohort study of factors that predict repeat admission for ADRs in older adults we found strong evidence that comorbidity from chronic disease rather than advancing age increases their rate of repeat ADRs. Comorbid congestive cardiac failure, diabetes, and peripheral vascular, chronic pulmonary, rheumatological, hepatic, renal, and malignant diseases were all strong predictors of readmissions for ADRs. Our results were consistent with those of earlier studies that a higher Charlson comorbidity index score,[@ref4] renal insufficiency,[@ref28] and diabetes[@ref29] were all risk factors for first time ADRs. We also found that comorbid cerebrovascular disease, dementia, and hemiplegia or paraplegia were associated with a reduced risk of repeat admission for ADRs. First admission for an ADR with a longer hospital stay, admissions in the most recent time period, and male sex also predicted repeat ADR admissions, with admission to private hospitals showing a reduced risk.

ADRs are acknowledged as a major health problem in older people.[@ref1] [@ref2] [@ref3] [@ref4] [@ref5] [@ref6] [@ref7] [@ref30] A meta-analysis of 68 observational studies reported that the proportion of admissions related to ADRs in older people was four times higher than in younger people.[@ref31] We found, however, that advancing age was not independently predictive of repeat admissions related to ADRs in people ≥60. This is consistent with results from previous studies that have examined the independent effects of age on first time ADRs.[@ref11] [@ref13] Other reported risk factors for first time ADRs include sex, multiple drug regimens, inappropriate use of drugs, alcohol intake, cognitive function, and depression.[@ref4] [@ref10] [@ref11] [@ref12] [@ref13] [@ref14] [@ref15] To our knowledge, however, the same risk factors for repeat ADRs have not been previously investigated.

Strengths and limitations
-------------------------

There are several potential explanations for the observed importance of comorbidity. Comorbidity might increase vulnerability to ADRs by impairing body systems---for example, cardiovascular, pulmonary, renal, and hepatic insufficiency can cause changes in pharmacokinetics and pharmacodynamics.[@ref28] There might be increased opportunity for drug interactions because of polypharmacy for multiple morbidities. Finally, Berkson's bias---that is, ADRs are more likely to be identified and diagnosed because of comorbid conditions increasing a person's contact with the health system.[@ref32] A reduced risk of repeat ADRs associated with admission to private hospital might be explained by private patients having generally better health or being socioeconomically advantaged and having stronger social supports. This latter theory, however, is inconsistent with the direct measure of least socioeconomic disadvantage used in this study, which had no effect (hazard ratio 0.94, 0.87 to 1.02).

An important limitation of the study was the absence of data in the hospital morbidity data system on specific drug doses and multiple drug regimens. Nevertheless, we did have information on the drug category primarily responsible for ADRs. We assessed the effect of each drug category by comparing it with the average risk of a repeat ADR from the 20 drug categories responsible for first time ADRs. Hormones, primarily systemic agents, and bacterial vaccines were associated with higher than average risks of repeat ADR, although the numbers in the bacterial vaccines group was small. The higher risk of repeat ADRs from hormones and primarily systemic agents (which include antineoplastic drugs) was expected as severe side effects of these drugs are well known. We examined the diagnoses in patients who had first time ADRs caused by bacterial vaccines and found that nearly 38% of these patients had malignant diseases treated with bacillus Calmette-Guerin (BCG) vaccine or other vaccine based immunotherapy. Hence, the increased effect on repeat ADRs observed in the category of bacterial vaccines was probably caused by the concomitant use of antineoplastic agents (part of "primarily systemic agents"). The age standardised rates of all cancers for males and females in 2005 were 356.1 and 260.9 per 100 000 person years, based on a publication from the Western Australia cancer registry.[@ref33] Hence, men have a higher incidence of cancer than women in Western Australia, which might explain the observed higher risk of repeat ADRs in men.

The risk of adverse drug effects might increase with increasing drug dose. Although we did not have specific data on drug dose for individuals in our population dataset, we investigated the extent to which doses were prescribed within the normal limits set by the manufacturers as documented in the Monthly Index of Medical Specialities (MIMS-Australia), a database containing approved product information from manufacturers for medicines used in Australia.[@ref34] We obtained data on pharmacy dispensing of drugs for discharge and outpatients for the year 2000 from the pharmacy department of one of the teaching hospitals in Western Australia. Analysis of prescribed doses for these drugs showed that nearly all (99.6%) were within the range recommended by the manufacturer as recorded in MIMS Australia.[@ref34]

The strengths of our study include the cohort design with population based and audited data of high quality,[@ref17] thus overcoming issues related to selection and recall biases as well as loss to follow-up. Loss to follow-up would have been small as interstate migration occurred in only 3.5% of residents in Western Australia during the 24 year study period.[@ref35] The longitudinal linked data allowed us to identify repeat ADRs in the same patient regardless of changes in the treating hospital. The fact that death records were linked to 69% of participants was consistent with a high level of completeness of follow-up. An important limitation of the study was that the administrative hospital morbidity data system is known to code only 60% of the 17 Charlson comorbid conditions relative to information obtained from chart review.[@ref23] False positive diagnoses of comorbid conditions, however, are infrequent for most conditions (range 0-1.5%).[@ref23] Although underascertainment of comorbidity is an issue in this study, it seems implausible that the levels of underascertainment would differ substantially between patients with first time ADR only and those with repeat ADRs. Another limitation was that the study focused only on ADRs that either caused hospital admission or extended hospital stay, whereas most ADRs (90%) are fairly minor and occur in the community without admission to hospital.[@ref36] ADRs resulting in admission, however, represent the most severe adverse side effects of medication use and lead to considerable morbidity and financial costs. They are thus arguably the most appropriate object of analysis.

As with other studies of this nature, reliability of ascertainment might vary because the presence and diagnosis of an ADR is subject to clinical judgment. The diagnosis of an ADR was made by senior hospital doctors (consultants and registrars) and junior doctors recorded them in text on a structured hospital separation abstract. This step in the process was subject to diagnostic error at a level that is usual in clinical practice. The second step in the process involved coding the text, including external causes or contributing factors, using the ICD-9, ICD-9-CM, or ICD-10-AM coding manuals (for different time periods). This was performed in each of the hospitals by qualified clinical coders who are trained in the use of the ICD codes and were able to obtain additional information from the medical notes as required. The accuracy of clinical coding (including E codes) is routinely checked by coding supervisors as well as by random internal audits.

We found that older adults who experienced an ADR during the most recent study period, 1995-9, had a 2.4-fold greater risk of recurrence than their counterparts in 1980-4. As the study was longitudinal, we need to consider the influence of factors that changed with time. The results are consistent with national drug consumption data that showed an increase in drug exposure in older Australians of 4.7% during 2000-1 alone.[@ref37] This increase greatly exceeded population growth, suggesting either a larger population at risk or a higher average level of drug exposure per patient. Our results, derived from population level data, suggest that there exists a strong temporal correlation between repeat ADRs in older adults and greater use of drugs in the community generally.[@ref30] [@ref38] While efforts to improve the coding of ADRs in hospital morbidity data systems during the observation period might have contributed to some of the observed rise in admissions for ADRs, an earlier validation study in Western Australia, involving a review of hospital charts, found a real increase in hospital morbidity caused by ADRs from 1980 to 1991.[@ref39]

Conclusions
-----------

This population based cohort study found that comorbidity and not advancing age predicted repeat admission for ADRs in patients aged over 60. Comorbid congestive cardiac failure, peripheral vascular, chronic pulmonary, rheumatological, hepatic, renal, and malignant diseases, and diabetes were the comorbid conditions most likely to predict readmission for ADRs from the therapeutic use of drugs. An apparent preventive effect was observed with comorbid cerebrovascular disease, dementia, and hemiplegia or paraplegia, possibly because such patients are under more consistent healthcare supervision. Careful and frequent monitoring of prescribed drugs in older adults with at risk comorbidities might prevent readmissions for ADRs. Evaluation of monitoring programmes delivered by local pharmacists, community nurses, and general practitioners might be the next step towards prevention.

### What is already known on this topic

1.  Adverse drug reactions (ADRs) are a major public health problem in older populations

2.  Repeat ADRs leading to hospital admission have increased at a greater rate than first time ADRs in older adults and by 2003 in Western Australia they had reached 30% of all ADRs

3.  Little information is available on risk factors that predict repeat ADRs

### What this study adds

1.  Comorbid congestive cardiac failure, diabetes, peripheral vascular, chronic pulmonary, hepatic, renal, rheumatological, and malignant diseases predict readmission for ADRs

2.  Comorbid cerebrovascular disease, dementia, and paraplegia seem to protect against repeat ADRs, possibly because such patients are under closer healthcare supervision
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